본문 바로가기
bar_progress

Text Size

Close

SK Bioscience Revamps Website to Enhance ESG Initiatives

SK Bioscience announced on the 7th that it has revamped its official ESG (Environmental, Social, and Governance) website to enhance transparency and accessibility of its ESG activities and strengthen communication with stakeholders.


SK Bioscience Revamps Website to Enhance ESG Initiatives Revamped SK Bioscience ESG Website
[Photo by SK Bioscience]

The newly launched ESG website features an improved user interface (UI) with an intuitive design and layout, making it more user-friendly and enhancing information accessibility. In particular, in line with the recent trend of publishing online reports to practice 'Zero Waste,' the sustainability management reports, which were published annually in booklet form since 2022, have been included on the webpage.


The ESG website is organized to allow users to easily grasp the key initiatives and major achievements in the areas of Environment (E), Social (S), and Governance (G). Additionally, last year’s ESG activities?▲Climate Change Response ▲Human Rights Management ▲Win-Win Management?are featured on the main page to improve access to the latest information. SK Bioscience plans to revamp the English ESG website within this month to enhance accessibility for global stakeholders.


SK Bioscience aims to simultaneously achieve economic value (EV) and social value (SV) through the advancement of ESG management via active investment and grow into a company that meets global standards. To firmly promote sustainable management, the company plans to proactively apply relevant domestic and international regulations and disclosure standards.


Previously, SK Bioscience received an A grade in the 2023 ESG evaluation conducted by Morgan Stanley Capital International (MSCI), earning high scores in areas such as ▲Human Resource Development ▲Healthcare Accessibility Enhancement ▲Hazardous Substance and Waste Management ▲Governance. Through continuous efforts to internalize ESG management, SK Bioscience’s rating has improved from a B grade in its first evaluation in 2021 to BBB in 2022, and then to A last year, achieving the highest rating in the domestic bio industry.


Jang Ki-ryong, Head of Strategy Planning at SK Bioscience, said, “ESG is a foundation and a key factor for sustainable growth and leap forward of a company. We will continue to strive for ESG management by simultaneously achieving financial and non-financial performance and strengthening communication with stakeholders.”


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top